CADL 株価推移チャート
CADL 財務
Candel Therapeutics Inc
$11.72
-0.67%
$-0.08
終値： Aug 14, 16:00:00 GMT-4
$11.5
-1.87%
$-0.22
アフターマーケット：Aug 14, 20:00:00 GMT-4
戻る
Candel Therapeutics Inc (CADL) 財務
主要データ
前終値
$11.8
始値
$11.74
当日レンジ
$11.05 - $11.94
52週レンジ
$4.35 - $11.5
取引高
2.0M
平均取引高
1.8M
配当利回り
--
1株当たり利益(TTM)
-0.98
時価総額
$842.6M
CADLとは何ですか？
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. The company is headquartered in Needham, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2021-07-27. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
